Short-Course Induction Treatment with Intrathecal Amphotericin B Lipid Emulsion for HIV Infected Patients with Cryptococcal Meningitis
Table 1
Baseline characteristics by treatment group.
Value
Standard Rx ()
Short i.t. Rx ()
value
Gender
Male
53 (67.95)
35 (77.78)
0.245
Female
25 (32.05)
10 (22.22)
Abnormal mental status or seizures
No
51 (65.38)
36 (80)
0.086
Yes
27 (34.62)
9 (20)
On antiretroviral therapy
No
39 (50)
20 (44.44)
0.552
Yes
39 (50)
25 (55.56)
CD4 cell count (cells/L)
0–25
20 (25.64)
10 (22.22)
0.753
26–50
18 (23.08)
12 (26.67)
51–100
11 (14.1)
9 (20)
>100
29 (37.18)
14 (31.11)
Age, mean (SD)
Years
36.72 (9.25)
38.29 (9.13)
0.362
White blood cells, mean (SD)
Cells/nL
6.24 (4.74)
6.42 (5.71)
0.862
Hemoglobin, mean (SD)
g/dL
9.18 (2.49)
9.43 (1.9)
0.538
CSF white cells, median (IQR)
Cells/mL
17 (6–76)
16 (4–40)
0.52
CSF: cerebrospinal fluid; IQR: interquartile range; i.t.: intrathecal; Rx: treatment. Data are presented as number (%) unless otherwise indicated. Standard Rx: two-week intravenous amphotericin B deoxycholate (AmBd). Short i.t. Rx: one week of intravenous AmBd and intrathecal AmB lipid emulsion. values were calculated using Chi2 test for categorical variables and -test (not assuming equal variances) for continuous variables.
